Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Rinnerthaler Gabriel |

** = Publikationen gelistet in SCI/SSCI/Pubmed

2025

Originalarbeit (Zeitschrift)

** El, Kababji, S; Mitsakakis, N; Jonker, E; Beltran-Bless, AA; Pond, G; Vandermeer, L; Radhakrishnan, D; Mosquera, L; Paterson, A; Shepherd, L; Chen, B; Barlow, W; Gralow, J; Savard, MF; Fesl, C; Hlauschek, D; Balic, M; Rinnerthaler, G; Greil, R; Gnant, M; Clemons, M; El, Emam, K Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.
J Med Internet Res. 2025; 27:e66821 Doi: 10.2196/66821 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gampenrieder, SP; Vaisband, M; Rinnerthaler, G; Weiss, L; Jaud, B; Sprenger, M; Greil, R A comparison of breast cancer incidence and cancer stages before and after the introduction of the Austrian national breast cancer screening program in the federal state of Salzburg : Real-world data from the Tumor Registry Salzburg.
Wien Klin Wochenschr. 2025; Doi: 10.1007/s00508-025-02508-8 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Egle, D; Bartsch, R; Schmitt, CA; Petzer, A; Balic, M; Petru, E; Denison, U; Singer, CF; Bjelic-Radisic, V; Gampenrieder, SP; Knauer, M; Sotlar, K; Brunner, C; Posch, F; Hlauschek, D; Sölkner, L; Bago-Horvath, Z; Filipits, M; Gili, M; Ritter, M; Wieser, V; Albertini, C; Zaborsky, N; Weiss, L; Marhold, M; Schneeweiss, B; Pusch, R; Gnant, M; Greil, R Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.
Nat Cancer. 2025; Doi: 10.1038/s43018-024-00890-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Klocker, EV; Egle, D; Bartsch, R; Rinnerthaler, G; Gnant, M Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.
Drugs. 2025; Doi: 10.1007/s40265-024-02144-y [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Breitenstein, U; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Zahn, MO; Perlova-Griff, L; Distelrath, A; Wuerstlein, R; Apel, K; Deuerling, N; Vannier, C; Bartsch, R; Jackisch, C; Mueller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Lueftner, D; Zaman, K; Schwitter, M; Harbeck, N Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine - interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR (n=300)
BREAST. 2025; 80: 103911 Doi: 10.1016/j.breast.2025.103911
Web of Science FullText FullText_MUG

 

2024

Originalarbeit (Zeitschrift)

** Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Zahn, MO; Wuerstlein, R; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Müller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinköthe, T; Resch, A; Valenti, R; Lüftner, D Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Breast Care (Basel). 2024; 19(1):1-9 Doi: 10.1159/000533657 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Sassmann, R; Gampenrieder, SP; Rieder, F; Johansson, T; Rinnerthaler, G; Castagnaviz, V; Lampl, K; Herfert, J; Kienberger, YT; Flamm, M; Schaffler-Schaden, D; Greil, R Electrotherapy as treatment for chemotherapy-induced peripheral neuropathy - a randomized controlled trial
FRONT NEUROL. 2024; 15: 1451456 Doi: 10.3389/fneur.2024.1451456 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Bartsch, R; Rinnerthaler, G; Petru, E; Egle, D; Gnant, M; Balic, M; Sliwa, T; Singer, C Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.
Wien Klin Wochenschr. 2024; 136(11-12):347-361 Doi: 10.1007/s00508-023-02254-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gnant, M; Balic, M; Singer, CF; Rinnerthaler, G; Pfeiler, G; Suppan, C; Grünberger, B; Strasser-Weippl, K; Castagnaviz, V; Heibl, S; Bartsch, R Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
MEMO-MAG EUR MED ONC. 2024; Doi: 10.1007/s12254-024-01012-5
Web of Science FullText FullText_MUG

 

** Klocker, EV; Hasenleithner, S; Bartsch, R; Gampenrieder, SP; Egle, D; Singer, CF; Rinnerthaler, G; Hubalek, M; Schmitz, K; Bago-Horvath, Z; Petzer, A; Heibl, S; Heitzer, E; Balic, M; Gnant, M Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.
Mol Oncol. 2024; Doi: 10.1002/1878-0261.13671
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Beheshti, M; Rinnerthaler, G; Farbod, A; Hitzl, W; Egle, D; Gampenrieder, SP; Bartsch, R; Balic, M; Greil, R; Gnant, M; Pirich, C Predictive role of baseline [18F]FDG PET/CT quantitative parameters for response to neoadjuvant treatment with atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer - a substudy of the ABCSG-52/ATHENE phase II trial
EUR J NUCL MED MOL I. 2024; 51: S481-S482. [Poster]
Web of Science

 

2023

Originalarbeit (Zeitschrift)

** Beltran-Bless, AA; Clemons, MJ; Fesl, C; Greil, R; Pond, GR; Balic, M; Vandermeer, L; Bjelic-Radisic, V; Singer, CF; Steger, GG; Helfgott, R; Egle, D; Sölkner, L; Gampenrieder, SP; Kacerovsky-Strobl, S; Suppan, C; Ritter, M; Rinnerthaler, G; Pfeiler, G; Fohler, H; Hlauschek, D; Hilton, J; Gnant, M Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
Eur J Cancer. 2023; 180:108-116 Doi: 10.1016/j.ejca.2022.12.003
Web of Science PubMed FullText FullText_MUG

 

** Gampenrieder, SP; Dezentjé, V; Lambertini, M; de, Nonneville, A; Marhold, M; Le, Du, F; Cortés, Salgado, A; Alpuim, Costa, D; Vaz, Batista, M; Chic, Ruché, N; Tinchon, C; Petzer, A; Blondeaux, E; Del, Mastro, L; Targato, G; Bertucci, F; Gonçalves, A; Viret, F; Bartsch, R; Mannsbart, C; Deleuze, A; Robert, L; Saavedra, Serrano, C; Gion, Cortés, M; Sampaio-Alves, M; Vitorino, M; Pecen, L; Singer, C; Harbeck, N; Rinnerthaler, G; Greil, R, , AGMT, Study, Group Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
ESMO Open. 2023; 8(1):100747 Doi: 10.1016/j.esmoop.2022.100747 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Grambozov, B; Kalantari, F; Beheshti, M; Stana, M; Karner, J; Ruznic, E; Zellinger, B; Sedlmayer, F; Rinnerthaler, G; Zehentmayr, F Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Radiother Oncol. 2023; 185:109728 Doi: 10.1016/j.radonc.2023.109728
Web of Science PubMed FullText FullText_MUG

 

** Huemer, F; Dunkl, C; Rinnerthaler, G; Schlick, K; Heregger, R; Emmanuel, K; Neureiter, D; Klieser, E; Deutschmann, M; Roeder, F; Greil, R; Weiss, L Management of metastatic colorectal cancer in patients ≥70 years - a single center experience.
Front Oncol. 2023; 13:1222951 Doi: 10.3389/fonc.2023.1222951 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Hecht, S; Scharinger, B; Schlintl, V; Rinnerthaler, G; Schlick, K; Heregger, R; Melchardt, T; Wimmer, A; Mühlbacher, I; Koch, OO; Neureiter, D; Klieser, E; Seyedinia, S; Beheshti, M; Greil, R; Weiss, L Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol.
J Cancer Res Clin Oncol. 2023; 149(7):3051-3064 Doi: 10.1007/s00432-022-04096-w [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2022

Originalarbeit (Zeitschrift)

** Bartsch, R; Gampenrieder, SP; Rinnerthaler, G; Petru, E; Egle, D; Petzer, A; Balic, M; Pluschnig, U; Sliwa, T; Singer, C Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.
Wien Klin Wochenschr. 2022; 134(1-2):63-72 Doi: 10.1007/s00508-021-01987-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stöger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Breast Care (Basel). 2022; 17(2): 137-145. Doi: 10.1159/000516157 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Gnant, M; Frantal, S; Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Artner-Matuschek, S; Kainberger, F; Ritter, M; Rinnerthaler, G; Sevelda, P; Bergh, J; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Gampenrieder, SP; Fohler, H; Jakesz, R; Fesl, C; Singer, C Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
NEJM Evid. 2022; 1(12):EVIDoa2200162 Doi: 10.1056/EVIDoa2200162
PubMed FullText FullText_MUG

 

** Lang, D; Brauner, A; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Kaiser, B; Greil, R; Lamprecht, B Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
Cancers (Basel). 2021; 14(1): Doi: 10.3390/cancers14010093 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Singer, C; Petru, E; Egle, D; Petzer, A; Pluschnig, U; Gampenrieder, SP; Pfeiler, G; Gnant, M; Grünberger, B; Krippl, P; Strasser-Weippl, K; Suppan, C; Brunner, C; Pusch, R; Sandholzer, M; Balic, M; Bartsch, R Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.
Wien Klin Wochenschr. 2022; 134(19-20):683-692 Doi: 10.1007/s00508-022-02082-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Schlintl, V; Huemer, F; Rinnerthaler, G; Melchardt, T; Winder, T; Reimann, P; Riedl, J; Amann, A; Eisterer, W; Romeder, F; Piringer, G; Ilhan-Mutlu, A; Wöll, E; Greil, R; Weiss, L Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
BMC Cancer. 2022; 22(1):51 Doi: 10.1186/s12885-021-09115-6 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Westphal, T; Gampenrieder, SP; Rinnerthaler, G; Balic, M; Posch, F; Dandachi, N; Hauser-Kronberger, C; Reitsamer, R; Sotlar, K; Radl, B; Suppan, C; Stöger, H; Greil, R Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT).
Breast Care (Basel). 2022; 17(1):1-9 Doi: 10.1159/000512467 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Clin Cancer Res. 2022; 28(4):697-707 Doi: 10.1158/1078-0432.CCR-21-3231 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2021

Originalarbeit (Zeitschrift)

** Dubsky, P; Van't, Veer, L; Gnant, M; Rudas, M; Bago-Horvath, Z; Greil, R; Lujinovic, E; Buresch, J; Rinnerthaler, G; Hulla, W; Moinfar, F; Egle, D; Herz, W; Dreezen, C; Frantal, S; Filipits, M A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort.
ESMO Open. 2021; 6(1):100006 Doi: 10.1016/j.esmoop.2020.100006 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, A; Balic, M; Heibl, S; Schmitt, C; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Hager, C; Andel, J; Hubalek, M; Knauer, M; Greil, R Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Breast Cancer Res. 2021; 23(1):112 Doi: 10.1186/s13058-021-01492-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gnant, M; Fitzal, F; Rinnerthaler, G; Steger, GG; Greil-Ressler, S; Balic, M; Heck, D; Jakesz, R; Thaler, J; Egle, D; Manfreda, D; Bjelic-Radisic, V; Wieder, U; Singer, CF; Melbinger-Zeinitzer, E; Haslbauer, F; Sevelda, P; Trapl, H; Wette, V; Wimmer, K; Gampenrieder, SP; Bartsch, R; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Soelkner, L; Fesl, C; Greil, R, , Austrian, Breast, and, Colorectal, Cancer, Study, Group Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
N Engl J Med. 2021; 385(5):395-405 Doi: 10.1056/NEJMoa2104162
Web of Science PubMed FullText FullText_MUG

 

** Huemer, F; Rinnerthaler, G; Jörg, B; Morre, P; Stegbuchner, B; Proksch, E; Fleimisch, S; Oberkofler, H; Kremser, I; Greil, R; Egle, A Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg-a report from the AGMT COVID-19 Registry.
Geroscience. 2021; 43(4):1877-1897 Doi: 10.1007/s11357-021-00352-y [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Kocher, F; Tymoszuk, P; Amann, A; Sprung, S; Salcher, S; Daum, S; Haybaeck, J; Rinnerthaler, G; Huemer, F; Kauffmann-Guerrero, D; Tufman, A; Seeber, A; Wolf, D; Pircher, A Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.
Lung Cancer. 2021; 159:84-95 Doi: 10.1016/j.lungcan.2021.06.020 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Magnes, T; Wagner, S; Thorner, AR; Neureiter, D; Klieser, E; Rinnerthaler, G; Weiss, L; Huemer, F; Schlick, K; Zaborsky, N; Steiner, M; Greil, R; Egle, A; Melchardt, T Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.
Cancers (Basel). 2021; 13(4): Doi: 10.3390/cancers13040650 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Magnes, T; Wagner, S; Thorner, AR; Neureiter, D; Klieser, E; Rinnerthaler, G; Weiss, L; Huemer, F; Zaborsky, N; Steiner, M; Weis, S; Greil, R; Egle, A; Melchardt, T Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
ESMO Open. 2021; 6(1):100012 Doi: 10.1016/j.esmoop.2020.100012 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Magnes, T; Wagner, SM; Melchardt, T; Weiss, L; Rinnerthaler, G; Huemer, F; Kopp, M; Gampenrieder, SP; Mayrbäurl, B; Füreder, T; Lenger, D; Andel, J; Egle, A; Greil, R Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Wien Klin Wochenschr. 2021; 133(21-22):1131-1136 Doi: 10.1007/s00508-021-01939-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Hubalek, M; Petru, E; Sandholzer, M; Andel, J; Balic, M; Melchardt, T; Hauser-Kronberger, C; Schmitt, CA; Ulmer, H; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Ther Adv Med Oncol. 2021; 13:17588359211042301 Doi: 10.1177/17588359211042301 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Müller, V; Balic, M; Zaman, K; Dieci, MV Expert Discussion: Immunotherapy in Breast Cancer - Ready for Prime Time?
Breast Care (Basel). 2021; 16(2):188-191 Doi: 10.1159/000515746 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Schlick, K; Hohla, F; Hamacher, F; Hackl, H; Hufnagl, C; Markus, S; Magnes, T; Gampenrieder, SP; Melchardt, T; Stättner, S; Hauser-Kronberger, C; Greil, R; Rinnerthaler, G Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
Future Sci OA. 2020; 7(2):FSO644 Doi: 10.2144/fsoa-2020-0128 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Balic, M; Rinnerthaler, G; Bartsch, R Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer.
Breast Care (Basel). 2021; 16(6):664-676 Doi: 10.1159/000518696 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Magnes, T; Wagner, S; Kiem, D; Weiss, L; Rinnerthaler, G; Greil, R; Melchardt, T Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.
Int J Mol Sci. 2021; 22(9): Doi: 10.3390/ijms22094981 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Fallbericht

** Heregger, R; Huemer, F; Hutarew, G; Hecht, S; Cheveresan, L; Kotzot, D; Schamschula, E; Rinnerthaler, G; Melchardt, T; Weiss, L; Greil, R Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature.
ESMO Open. 2021; 6(4):100233 Doi: 10.1016/j.esmoop.2021.100233 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2020

Originalarbeit (Zeitschrift)

** Huemer, F; Klieser, E; Neureiter, D; Schlintl, V; Rinnerthaler, G; Pagès, F; Kirilovsky, A; El, Sissy, C; Iglseder, W; Singhartinger, F; Jäger, T; Dinnewitzer, A; Zaborsky, N; Steiner, M; Greil, R; Weiss, L Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
J Clin Med. 2020; 9(9): Doi: 10.3390/jcm9092775 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Piringer, G; Schlintl, V; Hackl, H; Rinnerthaler, G; Thaler, J; Greil, R; Weiss, L Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy.
Cancers (Basel). 2020; 12(10): Doi: 10.3390/cancers12102812 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
J Clin Med. 2020; 9(6): Doi: 10.3390/jcm9061663 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Schaffler-Schaden, D; Sassmann, R; Johansson, T; Gampenrieder, SP; Rinnerthaler, G; Lampl, K; Herfert, J; Lenzhofer, C; Landkammer, YT; Rieder, F; Greil, R; Flamm, M; Niebauer, J Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy.
Medicine (Baltimore). 2020; 99(19):e20149 Doi: 10.1097/MD.0000000000020149 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Gampenrieder, SP; Castagnaviz, V; Rinnerthaler, G; Greil, R Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.
Cancer Manag Res. 2020; 12:10615-10629 Doi: 10.2147/CMAR.S235121 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Leisch, M; Geisberger, R; Melchardt, T; Rinnerthaler, G; Zaborsky, N; Greil, R Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Int J Mol Sci. 2020; 21(8): Doi: 10.3390/ijms21082856 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Korrektur

** Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Pharmacogenomics J. 2020; 20(2):350 Doi: 10.1038/s41397-019-0073-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2019

Originalarbeit (Zeitschrift)

** Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhofer, J; Westphal, T; Riedmann, M; Meissnitzer, T; Egger, H; Klaassen, Federspiel, F; Reitsamer, R; Hauser-Kronberger, C; Stering, K; Hergan, K; Mlineritsch, B; Greil, R Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Breast Cancer Res. 2019; 21(1): 19 Doi: 10.1186/s13058-018-1091-y [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Lang, D; Westphal, T; Gampenrieder, SP; Hutarew, G; Weiss, L; Hackl, H; Lamprecht, B; Rinnerthaler, G; Greil, R Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
J Clin Med. 2019; 8(7): Doi: 10.3390/jcm8071014 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Schlintl, V; Hecht, S; Hackl, H; Melchardt, T; Rinnerthaler, G; Greil, R; Weiss, L Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Clin Colorectal Cancer. 2019; 18(2): 159-166.e3. Doi: 10.1016/j.clcc.2019.04.003
Web of Science PubMed FullText FullText_MUG

 

** Lang, D; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Akbari, K; Granitz, M; Hutarew, G; Kaiser, B; Greil, R; Lamprecht, B Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Target Oncol. 2019; 14(6): 707-717. Doi: 10.1007/s11523-019-00679-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Schwarzenbacher, D; Klec, C; Pasculli, B; Cerk, S; Rinner, B; Karbiener, M; Ivan, C; Barbano, R; Ling, H; Wulf-Goldenberg, A; Stanzer, S; Rinnerthaler, G; Stoeger, H; Bauernhofer, T; Haybaeck, J; Hoefler, G; Jahn, SW; Parrella, P; Calin, GA; Pichler, M MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
Breast Cancer Res. 2019; 21(1):20 Doi: 10.1186/s13058-019-1104-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kurzbericht/Letter

** Huemer, F; Rinnerthaler, G; Lang, D; Hackl, H; Lamprecht, B; Greil, R Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics.
Ann Oncol. 2019; 30(4): 652-653. Doi: 10.1093/annonc/mdz021 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Rinnerthaler, G; Gampenrieder, SP; Greil, R HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Int J Mol Sci. 2019; 20(5): Doi: 10.3390/ijms20051115 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Originalarbeit (Zeitschrift)

** Bachmayer, S; Fastner, G; Vaszi, A; Iglseder, W; Kopp, P; Holzinger, J; Dinnewitzer, A; Rinnerthaler, G; Gampenrieder, SP; Emmanuel, K; Greil, R; Sedlmayer, F; Zehentmayr, F Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.
Strahlenther Onkol. 2018; 194(7): 627-637. Doi: 10.1007/s00066-018-1281-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Domenyuk, V; Gatalica, Z; Santhanam, R; Wei, X; Stark, A; Kennedy, P; Toussaint, B; Levenberg, S; Wang, J; Xiao, N; Greil, R; Rinnerthaler, G; Gampenrieder, SP; Heimberger, AB; Berry, DA; Barker, A; Quackenbush, J; Marshall, JL; Poste, G; Vacirca, JL; Vidal, GA; Schwartzberg, LS; Halbert, DD; Voss, A; Magee, D; Miglarese, MR; Famulok, M; Mayer, G; Spetzler, D Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Nat Commun. 2018; 9(1): 1219 Doi: 10.1038/s41467-018-03631-z [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Pulverer, W; Weinhaeusel, A; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Risch, A; Greil, R DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
Theranostics. 2018; 8(8): 2278-2288. Doi: 10.7150/thno.23544 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Rinnerthaler, G; Westphal, T; Hackl, H; Hutarew, G; Gampenrieder, SP; Weiss, L; Greil, R Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.
Oncotarget. 2018; 9(23): 16512-16520. Doi: 10.18632/oncotarget.24751 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Pharmacogenomics J. 2018; 18(3): 474-479. Doi: 10.1038/tpj.2017.37
Web of Science PubMed FullText FullText_MUG

 

** Melchardt, T; Magnes, T; Hufnagl, C; Thorner, AR; Ducar, M; Neureiter, D; Tränkenschuh, W; Klieser, E; Gaggl, A; Rösch, S; Rasp, G; Hartmann, TN; Pleyer, L; Rinnerthaler, G; Weiss, L; Greil, R; Egle, A Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Eur J Cancer. 2018; 93: 69-78. Doi: 10.1016/j.ejca.2018.01.064
Web of Science PubMed FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
BMC Cancer. 2018; 18(1):1074 Doi: 10.1186/s12885-018-4979-0 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Westphal, T; Rinnerthaler, G; Gampenrieder, SP; Niebauer, J; Thaler, J; Pfob, M; Fuchs, D; Riedmann, M; Mayr, B; Reich, B; Melchardt, T; Mlineritsch, B; Pleyer, L; Greil, R Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.
Cancer Med. 2018; 7(12): 5962-5972. Doi: 10.1002/cam4.1851 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Rinnerthaler, G; Gampenrieder, SP; Greil, R SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.
Memo. 2018; 11(3): 208-212. Doi: 10.1007/s12254-018-0433-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Greil, R ASCO 2018 highlights: metastatic breast cancer.
Memo. 2018; 11(4): 276-279. Doi: 10.1007/s12254-018-0450-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Westphal, T; Gampenrieder, SP; Rinnerthaler, G; Greil, R Cure in metastatic breast cancer.
Memo. 2018; 11(3): 172-179. Doi: 10.1007/s12254-018-0426-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Originalarbeit (Zeitschrift)

** Gampenrieder, SP; Hufnagl, C; Brechelmacher, S; Huemer, F; Hackl, H; Rinnerthaler, G; Romeder, F; Monzo, Fuentes, C; Morre, P; Hauser-Kronberger, C; Mlineritsch, B; Greil, R Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Pharmacogenomics J. 2017; 17(4): 344-350. Doi: 10.1038/tpj.2016.25
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Gampenrieder, SP; Rinnerthaler, G; Greil, R SABCS 2016: systemic therapy for metastatic breast cancer.
Memo. 2017; 10(2): 86-89. Doi: 10.1007/s12254-017-0326-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Originalarbeit (Zeitschrift)

** Melchardt, T; Hufnagl, C; Weinstock, DM; Kopp, N; Neureiter, D; Tränkenschuh, W; Hackl, H; Weiss, L; Rinnerthaler, G; Hartmann, TN; Greil, R; Weigert, O; Egle, A Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Oncotarget. 2016; 7(32): 51494-51502. Doi: 10.18632/oncotarget.9860 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Hackl, H; Gampenrieder, SP; Hamacher, F; Hufnagl, C; Hauser-Kronberger, C; Zehentmayr, F; Fastner, G; Sedlmayer, F; Mlineritsch, B; Greil, R miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.
Int J Mol Sci. 2016; 17(2): Doi: 10.3390/ijms17020156 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Gampenrieder, SP; Rinnerthaler, G; Greil, R CDK4/6 inhibition in luminal breast cancer.
Memo. 2016; 9: 76-81. Doi: 10.1007/s12254-016-0268-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Westphal, T; Rinnerthaler, G; Mlineritsch, B Adjuvant medical treatment for breast cancer in elderly and old women.
Memo. 2016; 9: 17-19. Doi: 10.1007/s12254-016-0258-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Originalarbeit (Zeitschrift)

** Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-21
Web of Science PubMed

 

2014

Originalarbeit (Zeitschrift)

** Gampenrieder, SP; Romeder, F; Muß, C; Pircher, M; Ressler, S; Rinnerthaler, G; Bartsch, R; Sattlberger, C; Mlineritsch, B; Greil, R Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Anticancer Res. 2014; 34(1): 227-33.
Web of Science PubMed

 

** Hohla, F; Hopfinger, G; Romeder, F; Rinnerthaler, G; Bezan, A; Stättner, S; Hauser-Kronberger, C; Ulmer, H; Greil, R Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Int J Oncol. 2014; 44(1): 319-26. Doi: 10.3892/ijo.2013.2176 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Gampenrieder, SP; Rinnerthaler, G; Greil, R Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?
Breast Care (Basel). 2014; 9(5): 323-30. Doi: 10.1159/000368710 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2013

Übersichtsarbeit

** Gampenrieder, SP; Rinnerthaler, G; Greil, R Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.
J Oncol. 2013; 2013: 732047 Doi: 10.1155/2013/732047 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum